In Vivo Validation of Trogocytosis in Neuroblastoma: A Potential Novel Mechanism of Resistance to Anti-GD2 Immunotherapy
Anti-GD2 monoclonal antibody (dinutuximab) has improved survival for high-risk neuroblastoma, but many children recur with resistant disease. We discovered that neuroblastoma cells treated with natural killer (aNK) cells and dinutuximab lead to tumor cell death and subsequent acquisition of neuroblastoma GD2 by aNK cells (GD2+aNK), a phenomenon called trogocytosis. We hypothesized that trogocytosis can be validated in vivo and that GD2+aNK cells would be targeted by aNK cells in the presence of dinutuximab in vitro.
Source: Journal of the American College of Surgeons - Category: Surgery Authors: Abigail K. Zamora, Michael John Zobel, Michael Allen Sheard, Robert Charles Seeger, Eugene Sung-Kyun Kim Tags: Pediatric surgery Source Type: research
More News: Brain | Children | Immunotherapy | Neuroblastoma | Neurology | Neurosurgery | Pediatrics | Surgery